IRIS Accounts Production v24.3.0.553 09303733 Board of Directors 1.5.23 30.4.24 30.4.24 a holding company. 0 0 0 0 true false true true false false true true true true true false Ordinary shares 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh093037332023-04-30093037332024-04-30093037332023-05-012024-04-30093037332022-04-30093037332022-05-012023-04-30093037332023-04-3009303733ns15:EnglandWales2023-05-012024-04-3009303733ns14:PoundSterling2023-05-012024-04-3009303733ns10:Director12023-05-012024-04-3009303733ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3009303733ns10:FRS1022023-05-012024-04-3009303733ns10:Audited2023-05-012024-04-3009303733ns10:FullAccounts2023-05-012024-04-3009303733ns10:OrdinaryShareClass12023-05-012024-04-3009303733ns10:Director32023-05-012024-04-3009303733ns10:RegisteredOffice2023-05-012024-04-3009303733ns10:Director22023-05-012024-04-3009303733ns5:CurrentFinancialInstruments2024-04-3009303733ns5:CurrentFinancialInstruments2023-04-3009303733ns5:RetainedEarningsAccumulatedLosses2023-04-3009303733ns5:RetainedEarningsAccumulatedLosses2024-04-300930373312023-05-012024-04-3009303733ns5:CostValuation2023-04-3009303733ns5:CurrentFinancialInstruments2023-05-012024-04-3009303733ns10:OrdinaryShareClass12024-04-3009303733ns5:RetainedEarningsAccumulatedLosses2023-05-012024-04-300930373322023-05-012024-04-30
REGISTERED NUMBER: 09303733 (England and Wales)















Strategic Report, Report of the Directors and

Financial Statements for the Year Ended 30 April 2024

for

Global Orphan Associates Limited

Global Orphan Associates Limited (Registered number: 09303733)






Contents of the Financial Statements
for the Year Ended 30 April 2024




Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 5

Statement of Comprehensive Income 9

Balance Sheet 10

Statement of Changes in Equity 11

Notes to the Financial Statements 12


Global Orphan Associates Limited

Company Information
for the Year Ended 30 April 2024







DIRECTORS: K Hinton
Mrs J M Sherry





REGISTERED OFFICE: Unit 1& 2
Alfred Eley Close
Swadlincote
DE11 0WU





REGISTERED NUMBER: 09303733 (England and Wales)





AUDITORS: Forvis Mazars LLP
Chartered Accountants and Statutory Auditor
First Floor
2 Chamberlain Square
Birmingham
B3 3AX

Global Orphan Associates Limited (Registered number: 09303733)

Strategic Report
for the Year Ended 30 April 2024

The directors present their strategic report for the year ended 30 April 2024.

REVIEW OF BUSINESS AND KEY PERFORMANCE INDICATORS
The principal activity of the company in the year under review was that of a holding company.

The company made no profit or loss for the year (2023: £nil) and had net assets of £nil (2023: £nil) at the year end.

PRINCIPAL RISKS AND UNCERTAINTIES
The Directors constantly review the risks and uncertainties in the market place and at entity level. The Company is a member of a group which operates in a niche market place which is driven by the general public's health needs. Whilst this remains a very competitive area, the business does not necessarily face the same level of risks and uncertainties as those experienced in the wider economy.

FINANCIAL RISK MANAGEMENT
The Company's operations expose it to a variety of financial risks that include the effects of credit risk, liquidity risk and cash flow risk.

The Company has defined policies and procedures which set out specific guidelines to manage credit risk, liquidity risk and cash flow risk and the circumstances when it would be appropriate to use financial instruments to manage these.

The Company holds meetings attended by the Directors or their representatives to discuss the current and future financial risk facing the Company in accordance with the Group's policies and appropriate decisions are made based on the market and business information available.

CREDIT RISK
This is the risk that one party to a financial instrument will cause a financial loss for that other party by failing to
discharge an obligation. Global Orphan Associates Limited's credit policies aim to avoid this within its operations.

LIQUIDITY RISK
This arises when an entity encounters difficulty in meeting obligations. The Company aims to mitigate risk by focussing on its working capital cycle.

CASH FLOW RISK
This is the risk of exposure to variability in cash flows that is attributable to a particular risk associated with a recognised asset or liability. The Company manages this risk through effective working capital management.

POST BALANCE SHEET EVENT
In May 2024, a subsidiary company, Healthnet Homecare (UK) Limited, purchased 100% of the ordinary share
capital of Healthcare Anywhere Limited for £140,000. Global Orphan Limited, another subsidiary company,
owned 50% of the ordinary share capital at the date of purchase and received £70,000 in return for its shares.

On 29 October 2024, the entire share capital of the Socius Pharma Group was purchased by Apollo 2024 Bidco Limited, the ultimate parent company of which is Apollo 2024 Topco Limited. Additional information can be found in the post balance events sheet note and the ultimate controlling party note.

FUTURE OUTLOOK
The group of which Global Orphan Associates Limited is a subsidiary is driven by the belief that the future of patient care will be increasingly delivered in the community and will be enabled through partnerships with the NHS and pharmaceutical companies. The group operates with the patient firmly at the centre and believes it is in a strong position for the future.

ON BEHALF OF THE BOARD:





K Hinton - Director


16 January 2025

Global Orphan Associates Limited (Registered number: 09303733)

Report of the Directors
for the Year Ended 30 April 2024

The directors present their report with the financial statements of the Company for the year ended 30 April 2024.

DIVIDENDS
No dividends will be distributed for the year ended 30 April 2024 (2023: £nil).

EVENTS SINCE THE END OF THE YEAR
In May 2024, a subsidiary company, Healthnet Homecare (UK) Limited, purchased 100% of the ordinary share
capital of Healthcare Anywhere Limited for £140,000. Global Orphan Limited, another subsidiary company,
owned 50% of the ordinary share capital at the date of purchase and received £70,000 in return for its shares.

On 29 October 2024, the entire share capital of the Socius Pharma Group was purchased by Apollo 2024 Bidco Limited, the ultimate parent company of which is Apollo 2024 Topco Limited. Additional information can be found in the post balance events sheet note and the ultimate controlling party note.

DIRECTORS
K Hinton has held office during the whole of the period from 1 May 2023 to the date of this report.

Other changes in directors holding office are as follows:

Mrs J M Sherry was appointed as a director after 30 April 2024 but prior to the date of this report.

M A Gordon ceased to be a director after 30 April 2024 but prior to the date of this report.

GOING CONCERN
The financial statements have been prepared on a going concern basis. The Directors have prepared a going concern assessment based on forecasts for a period up to April 2026, including realistic downside scenarios.

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. The Directors therefore continue to adopt the going concern basis in preparing the financial statements.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and as explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Global Orphan Associates Limited (Registered number: 09303733)

Report of the Directors
for the Year Ended 30 April 2024


AUDITORS
On 1 June 2024, the auditor, Mazars LLP, changed its name to Forvis Mazars LLP. The auditors, Forvis Mazars LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





K Hinton - Director


16 January 2025

Report of the Independent Auditors to the Members of
Global Orphan Associates Limited

Opinion
We have audited the financial statements of Global Orphan Associates Limited (the 'Company') for the year ended 30 April 2024, which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
_
In our opinion the financial statements:
- give a true and fair view of the state of the Company's affairs as at 30 April 2024 and of its result for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The other information comprises the information included in the Strategic Report, Report of the Directors and financial statements, other than the financial statements and our auditor's report thereon. The Directors are responsible for the other information contained within the Strategic Report and Report of the Directors. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Strategic Report and Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- the Strategic Report and Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Global Orphan Associates Limited


Matters on which we are required to report by exception
In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from
branches not visited by us; or

- the financial statements are not in agreement with the accounting records and returns; or

- certain disclosures of directors' remuneration specified by law are not made; or

- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Global Orphan Associates Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from
material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Based on our understanding of the company and its industry, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation, anti-money laundering regulation

To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to:

- Inquiring of management and, where appropriate, those charged with governance, as to whether the company is in
compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws and regulations;

- Inspecting correspondence, if any, with relevant licensing or regulatory authorities;

- Communicating identified laws and regulations to the engagement team and remaining alert to any indications of
non-compliance throughout our audit; and

- Considering the risk of acts by the company which were contrary to applicable laws and regulations, including fraud.

We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as tax legislation, pensions legislation and the Companies Act 2006.

In addition, we evaluated the directors' and management's incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of management override of controls, and determined that the principal risks related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, revenue recognition (which we pinpointed to the cut-off assertion), and significant one-off or unusual transactions.

Our audit procedures in relation to fraud included but were not limited to:

- Making enquiries of the directors and management on whether they had knowledge of any actual, suspected or
alleged fraud;

- Gaining an understanding of the internal controls established to mitigate risks related to fraud;

- Discussing amongst the engagement team the risks of fraud; and

- Addressing the risks of fraud through management override of controls by performing journal entry testing.

There are inherent limitations in the audit procedures described above and the primary responsibility for the prevention and detection of irregularities including fraud rests with management. As with any audit, there remained a risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal controls.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Report of the Independent Auditors to the Members of
Global Orphan Associates Limited


Use of our report
This report is made solely to the Company's members as a body in accordance with Chapter 3 of Part 16 of the
Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those
matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body for our audit work, for this report, or for the opinions we have formed.




Elisa Howe (Senior Statutory Auditor)
for and on behalf of Forvis Mazars LLP
Chartered Accountants and Statutory Auditor
First Floor
2 Chamberlain Square
Birmingham
B3 3AX

17 January 2025

Global Orphan Associates Limited (Registered number: 09303733)

Statement of Comprehensive Income
for the Year Ended 30 April 2024

30.4.24 30.4.23
Notes £    £   

TURNOVER - -
OPERATING PROFIT and
PROFIT BEFORE TAXATION - -

Tax on profit 5 - -
PROFIT FOR THE FINANCIAL YEAR - -

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR THE
YEAR

-

-

Global Orphan Associates Limited (Registered number: 09303733)

Balance Sheet
30 April 2024

30.4.24 30.4.23
Notes £    £    £    £   
FIXED ASSETS
Investments 6 780 780

CREDITORS
Amounts falling due within one year 7 780 780
NET CURRENT LIABILITIES (780 ) (780 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

-

-


RESERVES - -

The financial statements were approved by the Board of Directors and authorised for issue on 16 January 2025 and were signed on its behalf by:





K Hinton - Director


Global Orphan Associates Limited (Registered number: 09303733)

Statement of Changes in Equity
for the Year Ended 30 April 2024

Retained Total
earnings equity
£    £   

Changes in equity
Profit for the year - -
Balance at 30 April 2023 - -

Changes in equity
Profit for the year - -
Balance at 30 April 2024 - -

Global Orphan Associates Limited (Registered number: 09303733)

Notes to the Financial Statements
for the Year Ended 30 April 2024

1. STATUTORY INFORMATION

Global Orphan Associates Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company's functional and presentational currency is the Pound Sterling rounded to the nearest pound (£).

Financial Reporting Standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

the requirements of Section 7 Statement of Cash Flows;
the requirement of paragraph 3.17(d);
the requirements of paragraphs 11.42, 11.44, 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
the requirements of paragraphs 12.26, 12.27, 12.29(a), 12.29(b) and 12.29A;
the requirements of paragraphs 26.18(b), 26.19 to 26.21 and 26.23;
the requirements of paragraphs 29.28(b) and 29.29;
the requirement of paragraph 33.7.

This information is included in the consolidated financial statements of Socius Pharma Limited as at 30 April 2024 and those financial statements can be obtained from Companies House.

Preparation of consolidated financial statements
The financial statements contain information about Global Orphan Associates Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertaking are included by full consolidation in the consolidated financial statements of its parent, Socius Pharma Limited, York House, Main Street, Ullesthorpe, Leicestershire, LE17 5BT.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Going concern
The financial statements have been prepared on a going concern basis. The Directors have prepared a going concern assessment based on forecasts for a period up to April 2026, including realistic downside scenarios.

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. The Directors therefore continue to adopt the going concern basis in preparing the financial statements.

Investments in subsidiaries
Investments in subsidiary and associate undertakings are recognised at cost less impairment.

Investments in subsidiary and associate undertakings are reviewed for any indication that they may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in the Income Statement.


Global Orphan Associates Limited (Registered number: 09303733)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In applying the Company's accounting policies, the Directors are required to make judgements and estimations in determining the carrying amounts of assets and liabilities. The Directors' judgements and estimations are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements and estimations, the actual results and outcomes may differ. The Directors have not made any material judgements or estimations in the process of applying the Company's accounting policies.

4. OPERATING PROFIT

The results in the Income Statement were derived from continuing activities.

The company has no recognised gains or losses for the year other than the results included in the Income Statement.

5. TAXATION

Analysis of the tax charge
No liability to UK corporation tax arose for the year ended 30 April 2024 nor for the year ended 30 April 2023.

6. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 May 2023
and 30 April 2024 780
NET BOOK VALUE
At 30 April 2024 780
At 30 April 2023 780

Global Orphan Associates Limited (Registered number: 09303733)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

6. FIXED ASSET INVESTMENTS - continued

The share capital of subsidiary undertakings is designated as ordinary shares.


Subsidiary undertaking

Holding

Activity
Country of
incorporation
Registered
office


Global Orphan Limited


80%
Consultancy
and pharmacy
services

England &
Wales


(1


)

Healthnet Homecare Limited*

75%
Holding
company
England &
Wales

(2

)


Healthnet Homecare (UK) Limited*


75%
Nursing and
pharmacy
services

England &
Wales


(2


)

L F & E Refrigerated Transport Limited*

75%
Transportation
services
England &
Wales

(3

)
* Held by a subsidiary undertaking

(1) York House, Main Street, Ullesthorpe, Lutterworth, Leicestershire, LE17 5BT

(2) Unit 1 & 2 Alfred Eley Close, Swadlincote, DE11 0WU

(3) Ripley House, Ripley Drive, Normanton, West Yorkshire WF6 1QT

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Other creditors 780 780

Other creditors are owed by other group undertakings and are interest free and repayable on demand.

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.4.24 30.4.23
value: £    £   
1 Ordinary shares £0.01 - -

9. RESERVES
Retained
earnings
£   

Profit for the year -
At 30 April 2024 -

Global Orphan Associates Limited (Registered number: 09303733)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

10. RELATED PARTY DISCLOSURES

The Company has entered into transactions, in the ordinary course of business, with non-wholly owned group entities and related parties.

Transactions entered into and trading balances outstanding as at 30 April 2024 were as follows:


Sales

Interest

Amounts due
Amounts
owed
£   £   £   £   
Global Orphan Limited---780

Transactions entered into and trading balances outstanding as at 30 April 2023 were as follows:



Sales

Interest

Amounts due
Amounts
owed
£   £   £   £   
Global Orphan Limited---780

11. POST BALANCE SHEET EVENTS

In May 2024, a subsidiary company, Healthnet Homecare (UK) Limited, purchased 100% of the ordinary share capital of Healthcare Anywhere Limited for £140,000. Global Orphan Limited, another subsidiary company, owned 50% of the ordinary share capital at the date of purchase and received £70,000 in return for its shares.

On the 29 October 2024, Apollo 2024 Bidco Limited purchased 100% of the ordinary share capital of Socius Pharma Limited, 490 A ordinary shares and 2,000 B ordinary shares in Global Orphan Limited and 227 B ordinary shares of Healthnet Homecare Limited. Apollo 2024 Bidco Limited is wholly owned by Apollo 2024 Holdco Limited, which is in turn wholly owned by Apollo 2024 Midco Limited, which is in turn wholly owned by Apollo 2024 Topco Limited. As a result of the purchase Apollo 2024 Topco Limited owns the entire issued share capital of the Group. Apollo 2024 Topco Limited is majority owned by CBPE Capital Fund X LP, and accordingly CBPE Capital LLP became the company’s ultimate controlling entity at that date.

On 29 October 2024, a charge was entered into with Barclays Bank plc with fixed and floating charges over the property and undertakings of the company and which contains a negative pledge. Details of the charge can be obtained from Companies House.

12. ULTIMATE CONTROLLING PARTY

The immediate parent undertaking at the Balance Sheet date was Socius Pharma Limited, a company incorporated in England and Wales. Socius Pharma Limited was regarded by the directors as being the company's ultimate parent company and ultimate controlling entity as at the Statement of Financial Position Date. The company in which the results of this Company are consolidated for the year ended 30 April 2024 is Socius Pharma Limited. Copies of Socius Pharma Limited's financial statements can be obtained from Companies House.

As a result of the transaction described in the post balance sheet event note, on 29 October 2024, Apollo 2024 Topco Limited became company's ultimate parent company and CBPE Capital LLP became its ultimate controlling entity. Copies of Apollo 2024 Topco Limited’s financial statements can be obtained from Companies House.